Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.42 |
| ▸ | WNT1 | P04628 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058598 | 0.87 | PRMT5 (0.47) | CYP3A4PDE5APDE4APDE4BPDE4C | |
| SCHEMBL4054205 | 0.87 | SCD (0.44) | SCDCYP3A4PDE5APDE4APDE4B | |
| SCHEMBL13608320 | 0.85 | WNT1 (0.39) | SCDWNT1F2F10PLG | |
| SCHEMBL4056658 | 0.84 | SCD (0.51) | SCDCYP3A4PRMT5AURKADHODH | |
| SCHEMBL4049461 | 0.82 | SCD (0.52) | SCDCYP3A4PDE5AAURKA | |
| SCHEMBL4054481 | 0.82 | SCD (0.51) | SCDCYP3A4AURKADHODH | |
| SCHEMBL4057922 | 0.81 | AURKA (0.48) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4051426 | 0.81 | AURKA (0.42) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4059930 | 0.81 | SCD (0.50) | SCDCYP3A4PDE5APDE4APDE4B | |
| SCHEMBL4226507 | 0.81 | SCD (0.48) | SCDCYP3A4PRMT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | SCD 4559/4885CYP3A4 886/4885PDE5A 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.